TLR4 activation has been shown to promote inflammation, podocyte and tubular epithelial cell injury, and renal interstitial fibrosis in both in vivo and in vitro experiments under high-glucose conditions, suggesting that TLR4 is a potential therapeutic target for DKD [69]. Here, TLR4 is linked to diabetic kidney disease.